#Q4FY23
Rev: 64 vs 36 Cr
EPS: 16.94 vs 3.78 YoY vs 8.48 QoQ
Forward PE : single digit!
Did you know its fortunes are linked to Coal India?
Something big is happening !!
Insider scoop on Eimco Elecon ⬇️
*If useful, please share!!
Business:
Eimco Elecon has a near monopoly in the underground coal mining equipment industry in India, with healthy market share backed by an extensive after-sales service network
🔸Long standing relations with Coal India (CIL) & The Singareni Collieries Company Ltd. (SCCL)
Background
Lets understand operations of Coal India before we get to the big trigger for #EimcoElecon??
India accounts for 12.5% of global coal consumption.
In FY22, out of 622.6 million tonnes of coal mined, nearly 96%, was opencast (OC) coal
But,There is a problem with OC🔰
Result JUST AMAZING🔥
EPS H1 FY23 22.6 vs 15.7 H2 vs 3.3 H1Fy22
EBITDA to Cashflow 75% vs 105% QoQ
Pref issue(1.85%) to Mr.Ashish Kacholia at 700
Wanna know more on KMEW, how they gained MOAT in this biz is aweinspiring!!🧵
Management
About CEO: Mr. Sujay Kewalramani has gained extensive business experience of over 15 years in the field of ship building, repairing, dredging by working in Shipping majors - L&T Shipbuilding, Mercator Limited and Adani Ports & SEZ Ltd
KMEW started as a small ship-repair unit in 2015 and has since evolved into a dredging and ship-owning company providing essential services to minor and major ports
Geographical presence expands all the way starting form Kandla Port in the West to Calcutta port in East of India
Diagnostic stocks have been hit hard lately.Why?
Too many new entrants, more competition & price war.
Is there a silver lining somewhere?
More the healthcare sector expands more the business to whom? May be a labware supplier??
I think so & that's why I like Tarsons Products🧵
Tarsons products is a leading high quality plastic labware supplier to Pharma,CRO,Diagnostics and research industry with 39+ years of experience in lifesciences
It has established pan-India distribution & few to have global export network with 45+ distributors across 40 nations.
Why now?
Favourable Environment
Covid has enabled investment in healthcare infra, research & tests
Meditourism, CRO services will further expand market.
Technically, stock has broken out of range with volumes indicating investor interest.
Revenues up 30% YOY, PAT up 46% YOY